Related Experiment Video
Updated: Oct 23, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Right Heart Catheterization in Cardiogenic Shock Is Associated With Improved Outcomes: Insights From the Nationwide
Sagar Ranka1, Ioannis Mastoris1, Navin K Kapur2
1Department of Cardiovascular Medicine The University of Kansas Health SystemUniversity of Kansas School of Medicine Kansas City KS.
Insights
Right heart catheterization (RHC) in cardiogenic shock patients improved survival and reduced readmissions. This study highlights RHC
Area of Science:
- Cardiology
- Critical Care Medicine
- Health Services Research
Background:
- The clinical utility of right heart catheterization (RHC) remains a subject of ongoing discussion.
- Investigating the real-world impact of RHC in patients experiencing cardiogenic shock is crucial.
Purpose of the Study:
- To assess the influence of RHC on management strategies, complications, and patient outcomes during index hospitalization.
- To evaluate the effect of RHC on 30-day readmission rates in cardiogenic shock patients.
Main Methods:
- Utilized the Nationwide Readmissions Database (NRD) from 2016-2017.
- Identified 236,156 hospitalizations for cardiogenic shock using ICD-10 codes.
- Compared outcomes between patients who underwent RHC (n=25,840) and those who did not.
Main Results:
- The RHC group exhibited lower in-hospital mortality (25.8% vs. 39.5%) and stroke rates (3.1% vs. 3.4%).
- Thirty-day readmission rates (18.7% vs. 19.7%) and mortality upon readmission (7.9% vs. 9.3%) were reduced in the RHC cohort.
- Adjusted analyses confirmed RHC was linked to lower mortality, stroke, and readmissions, alongside increased advanced heart failure therapy utilization.
Conclusions:
- Right heart catheterization in cardiogenic shock patients is associated with improved clinical outcomes.
- RHC use correlates with a higher likelihood of receiving advanced heart failure therapies.
- Further randomized controlled trials are warranted to validate these findings.
Abstract:
Background The usefulness of right heart catherization (RHC) has long been debated, and thus, we aimed to study the real-world impact of the use of RHC in cardiogenic shock. Methods and Results In the Nationwide Readmissions Database using International Classification of Diseases, Tenth Revision (ICD-10), we identified 236 156 patient hospitalizations with cardiogenic shock between 2016 and 2017. We sought to evaluate the impact of RHC during index hospitalization on management strategies, complications, and outcomes as well as on 30-day readmission rate. A total 25 840 patients (9.6%) received RHC on index admission. The RHC group had significantly more comorbidities compared with the non-RHC group. During the index admission, the RHC group had lower death (25.8% versus 39.5%, P<0.001) and stroke rates (3.1% versus 3.4%, P<0.001). Thirty-day readmission rates (18.7% versus 19.7%, P=0.04) and death on readmission (7.9% versus 9.3%, P=0.03) were also lower in the RHC group. After adjustment, RHC was associated with lower index admission mortality (odds ratio, 0.69; 95% CI, 0.66-0.72), lower stroke rate (odds ratio, 0.81; 95% CI, 0.72-0.90), lower 30-day readmission (odds ratio, 0.83; 95% CI, 0.78-0.88), and higher left ventricular assist device implantations/orthotopic heart transplants (odds ratio, 6.05; 95% CI, 4.43-8.28) during rehospitalization. Results were not meaningfully different after excluding patients with cardiac arrest. Conclusions RHC use in cardiogenic shock is associated with improved outcomes and increased use of downstream advanced heart failure therapies. Further blinded randomized studies are required to confirm our findings.
More Related Videos
Related Concept Videos
Cardiac Catheterization II: Right Heart Catheterization
Cardiac Catheterization I: Pre-Procedure Overview
Cardiac Catheterization III: Left Heart Catheterization
Cardiac Catheterization IV: Nursing Management
Acute Coronary Syndrome IV: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy

